Señales en vivo de CDXI | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 dic 2023 @ 09:38):

Stats
Volumen de hoy	1.00
Volumen promedio	0.00
Capitalización de mercado	4.00
EPS	$-1.740 ( 2021-05-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2014-02-24	Paulson Capital (delaware) Corp.	Buy	500 000	Common Stock
2014-02-24	Paulson Cardax Investments 1 Llc	Buy	500 000	Common Stock
2014-02-07	Paulson Capital (delaware) Corp.	Buy	1 068 477	Warrants (right to buy)
2014-02-07	Paulson Cardax Investments 1 Llc	Buy	1 068 477	Warrants (right to buy)
2014-02-07	Paulson Capital (delaware) Corp.	Buy	0	Common Stock

INSIDER POWER
0.00
Last 4 transactions
Buy: 3 136 954 \| Sell: 0

Volumen Correlación

Largo: -0.01 (neutral)

Corto: 0.00 (neutral)

Signal:(99.872) Neutral

Cardax, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cardax, Inc. Correlación - Moneda/Commodity

0.00
( neutral )

-0.34
( neutral )

0.00
( neutral )

Cardax, Inc. Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$0

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$0

FY	2020
Ingresos:	$538 946
Beneficio Bruto:	$342 816 (63.61 %)
EPS:	$-6.79

FY	2019
Ingresos:	$710 949
Beneficio Bruto:	$365 556 (51.42 %)
EPS:	$-7.49

Financial Reports:

No articles found.

Cardax, Inc.

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.